|
1
|
Estey E: Why is progress in acute myeloid
leukemia so slow? Semin Hematol. 52:243–248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lichtenegger FS, Krupka C, Köhnke T and
Subklewe M: Immunotherapy for acute myeloid leukemia. Semin
Hematol. 52:207–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coombs CC, Tallman MS and Levine RL:
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol.
13:305–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marucci G: Treatment of pituitary
neoplasms with temozolomide: A review. Cancer. 117:4101–4102. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Falfushynska HI, Gnatyshyna LL and Stoliar
OB: Population-related molecular responses on the effect of
pesticides in Carassius auratus gibelio. Comp Biochem Physiol C
Toxicol Pharmacol. 155:396–406. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rao GW, Wang C, Wang J, Zhao ZG and Hu WX:
Synthesis, structure analysis, antitumor evaluation and 3D-QSAR
studies of 3,6-disubstituted-dihydro-1,2,4,5-tetrazine derivatives.
Bioorg Med Chem Lett. 23:6474–6480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nhu D, Duffy S, Avery VM, Hughes A and
Baell JB: Antimalarial
3-arylamino-6-benzylamino-1,2,4,5-tetrazines. Bioorg Med Chem Lett.
20:4496–4498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tabassum S, Parveen M, Ali A, Alama M,
Ahmad Anis, UKhan A and Khana RA: Synthesis of
Aryl-1,2,4,5-tetrazinane-3-thiones, in vitro DNA binding studies,
nuclease activity and its antimicrobial activity. J Mol Structure.
1020:33–40. 2012. View Article : Google Scholar
|
|
9
|
Stanovnik B, Grošelj U and Svete J:
9.12–1,2,4,5-TetrazinesComprehensive Heterocyclic Chemistry III.
Katritzky AR, Ramsden CA, Scriven EFV and Taylor RJK: Elsevier;
Oxford: pp. 641–714. 2008
|
|
10
|
Rao GW and Hu WX: Synthesis, X-ray
crystallographic analysis and antitumor activity of
1-acyl-3,6-disubstituted phenyl-1,4-dihydro-1,2,4,5-tetrazines.
Bioorg Med Chem Lett. 15:3174–3176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rao GW and Hu WX: Synthesis, structure
analysis and antitumor activity of
3,6-disubstituted-1,4-dihydro-1,2,4,5-tetrazine derivatives. Bioorg
Med Chem Lett. 16:3702–3705. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu WX, Rao GW and Sun YQ: Synthesis and
antitumor activity of s-tetrazine derivatives. Bioorg Med Chem
Lett. 14:1177–1181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiu LN, Zhou YL, Wang ZN, Huang Q and Hu
WX: ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia
cells. Int J Oncol. 41:533–540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qiu L, Liu J, Wang Z, Hu W, Huang Q and
Zhou Y: ZGDHu-1 and fludarabine have a synergistic effect on
apoptosis of chronic lymphocytic leukemia cells. Oncol Rep.
34:1239–1248. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen SF, Xia J, Lv YP, Liu JL, Li WX, Yu
XP, Hu WX and Zhou YL:
N,N'-di-(m-methylphenyi)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide
(ZGDHu-1) suppresses the proliferation of PANC-1 pancreatic cancer
cells via apoptosis and G2/M cell cycle arrest. Oncol Rep.
33:1915–1921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia J, Chen SF, Lv YP, Lu LN, Hu WX and
Zhou YL: ZGDHu-1 induces G2/M phase arrest and apoptosis
in Kasumi-1 cells. Mol Med Rep. 11:3398–3404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou YL, Lu YP, Hu WX, Qiu LN, Wang WS and
Liu JD: Effects of N, N-di-(m-methylphenyl)-3,6-dimethyl-1,
4-dihydro-1,2,4,5-tetrazine-1,4-dicarboxamide (ZGDhu-1) on SHI-1
leukemia cells in vitro. Zhonghua Xue Ye Xue Za Zhi. 27:361–365.
2006.(In Chinese). PubMed/NCBI
|
|
18
|
Zhou YL, Lü YP, Hu WX, Qiu LN, Wang WS, Wu
JG and Liu JD: Effects of N, N'-Di-(m-methylphenyi)-3,6-dimethyl-1,
4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamide on proliferation,
apoptosis and differentiation of NB4 leukemia cells in vitro.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 14:880–886. 2006.(In Chinese).
PubMed/NCBI
|
|
19
|
Zhou YL, Hu WX, Lü YP, Qiu LN, Wang WS,
Yang ZY, Liu JD and Rao GW: Effect of ZGDHu-1 on proliferation and
apoptosis of A549 cells in vitro and antitumor activity in vivo.
Yao Xue Xue Bao. 42:26–34. 2007.(In Chinese). PubMed/NCBI
|
|
20
|
Zhou YL, Lü YP, Hu WX, Qiu LN, Wang WS,
Liu JD and Wu JG: ZGDHu-1-inducing apoptosis of SHI-1 leukemia
cells and its molecular mechanism. Zhongguo Shi Yan Xue Ye Xue Za
Zhi. 15:483–489. 2007.(In Chinese). PubMed/NCBI
|
|
21
|
Zhou YL, Xu WL, Wang ZN, Lü YP and Hu WX:
Apoptosis of human lung carcinoma cell line EBC-1 induced by
N,N'-di-(m-methylphenyl)-3,6-dimethyl-1,4-dihydro-1,2,4,5-tetrazine-1,4-dicarboamid
e and its molecular mechanism. Zhonghua Zhong Liu Za Zhi.
32:886–891. 2010.(In Chinese). PubMed/NCBI
|
|
22
|
Zhou YL, Chen LC and Lü YP: Inhibition
effects of ZGDHu-1 on proteasome in Kasumi-1 cells. Zhonghua Xue Ye
Xue Za Zhi. 33:61–63. 2012.(In Chinese). PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang
Y and Ceng J: A new human acute monocytic leukemia cell line SHI-1
with t (6;11) (q27;q23), p53 gene alterations and high
tumorigenicity in nude mice. Haematologica. 90:766–775.
2005.PubMed/NCBI
|
|
25
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lowe SW and Lin AW: Apoptosis in cancer.
Carcinogenesis. 21:485–495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferrara F and Del Vecchio L: Acute myeloid
leukemia with t(8;21)/AML1/ETO: A distinct biological and clinical
entity. Haematologica. 87:306–319. 2002.PubMed/NCBI
|
|
28
|
Murray AW: Recycling the cell cycle:
Cyclins revisited. Cell. 116:221–234. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Santo L, Siu KT and Raje N: Targeting
cyclin-dependent kinases and cell cycle progression in human
cancers. Semin Oncol. 42:788–800. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stark GR and Taylor WR: Control of the
G2/M transition. Mol Biotechnol. 32:227–248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bosman MC, Schuringa JJ and Vellenga E:
Constitutive NF-κB activation in AML: Causes and treatment
strategies. Crit Rev Oncol Hematol. 98:35–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guzman ML, Neering SJ, Upchurch D, Grimes
B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear
factor-kappaB is constitutively activated in primitive human acute
myelogenous leukemia cells. Blood. 98:2301–2307. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baumeister W, Walz J, Zühl F and Seemüller
E: The proteasome: Paradigm of a self-compartmentalizing protease.
Cell. 92:367–380. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ciechanover A: The ubiquitin-proteasome
pathway: On protein death and cell life. EMBO J. 17:7151–7160.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adams J: The proteasome: A suitable
antineoplastic target. Nat Rev Cancer. 4:349–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schwartz R and Davidson T: Pharmacology,
pharmacokinetics and practical applications of bortezomib. Oncology
(Williston Park). 18 14 Suppl 11:S14–S21. 2004.
|
|
38
|
Chen D and Dou QP: The
ubiquitin-proteasome system as a prospective molecular target for
cancer treatment and prevention. Curr Protein Pept Sci. 11:459–470.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen W, Lee J, Cho SY and Fine HA:
Proteasome-mediated destruction of the cyclin a/cyclin-dependent
kinase 2 complex suppresses tumor cell growth in vitro and in vivo.
Cancer Res. 64:3949–3957. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Diehl JA, Zindy F and Sherr CJ: Inhibition
of cyclin D1 phosphorylation on threonine-286 prevents its rapid
degradation via the ubiquitin-proteasome pathway. Genes Dev.
11:957–972. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Blagosklonny MV: P53: An ubiquitous target
of anticancer drugs. Int J Cancer. 98:161–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kalejta RF and Shenk T:
Proteasome-dependent, ubiquitin-independent degradation of the Rb
family of tumor suppressors by the human cytomegalovirus pp71
protein. Proc Natl Acad Sci USA. 100:pp. 3263–3268. 2003,
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li B and Dou QP: Bax degradation by the
ubiquitin/proteasome-dependent pathway: Involvement in tumor
survival and progression. Proc Natl Acad Sci USA. 97:pp. 3850–3855.
2000, View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pagano M, Tam SW, Theodoras AM,
Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M:
Role of the ubiquitin-proteasome pathway in regulating abundance of
the cyclin-dependent kinase inhibitor p27. Science. 269:682–685.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen ZJ: Ubiquitin signalling in the
NF-kappaB pathway. Nat Cell Biol. 7:758–765. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Martens JH, Brinkman AB, Simmer F,
Francoijs KJ, Nebbioso A, Ferrara F, Altucci L and Stunnenberg HG:
PML-RARalpha/RXR alters the epigenetic landscape in acute
promyelocytic leukemia. Cancer Cell. 17:173–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li J, Zhu H, Hu J, Mi J, Chen S, Chen Z
and Wang Z: Progress in the treatment of acute promyelocytic
leukemia: Optimization and obstruction. Int J Hematol. 100:38–50.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Roussel MJ and Lanotte M: Maturation
sensitive and resistant t (15;17) NB4 cell lines as tools for APL
physiopathology: Nomenclature of cells and repertory of their known
genetic alterations and phenotypes. Oncogene. 20:7287–7291. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Špaček M: Small molecules in the treatment
of chronic lymphocytic leukemia in 2015 and in the near future.
Klin Onkol. 28 Suppl 3:3S45–3S49. 2015.(In Czech). View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Huang Y, Wu JZ, Li JY and Xu W: Know the
enemy as well as the weapons in hand: The aberrant death pathways
and therapeutic agents in chronic lymphocytic leukemia. Am J Cancer
Res. 5:2361–2375. 2015.PubMed/NCBI
|
|
51
|
Dighiero G and Hamblin TJ: Chronic
lymphocytic leukaemia. Lancet. 371:1017–1029. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Buggins AG and Pepper CJ: The role of
Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res.
34:837–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Loeder S, Zenz T, Schnaiter A, Mertens D,
Winkler D, Döhner H, Debatin KM, Stilgenbauer S and Fulda S: A
novel paradigm to trigger apoptosis in chronic lymphocytic
leukemia. Cancer Res. 69:8977–8986. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Pepper C, Hoy T and Bentley DP: Bcl-2/Bax
ratios in chronic lymphocytic leukaemia and their correlation with
in vitro apoptosis and clinical resistance. Br J Cancer.
76:935–938. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pepper C, Thomas A, Hoy T and Bentley P:
Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is
mediated through failed Bax induction and selection of high
Bcl-2-expressing subclones. Br J Haematol. 104:581–588. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Molica S, Dattilo A, Giulino C, Levato D
and Levato L: Increased bcl-2/bax ratio in B-cell chronic
lymphocytic leukemia is associated with a progressive pattern of
disease. Haematologica. 83:1122–1124. 1998.PubMed/NCBI
|
|
57
|
Pepper C, Lin TT, Pratt G, Hewamana S,
Brennan P, Hiller L, Hills R, Ward R, Starczynski J, Austen B, et
al: Mcl-1 expression has in vitro and in vivo significance in
chronic lymphocytic leukemia and is associated with other poor
prognostic markers. Blood. 112:3807–3817. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Anderson MA, Huang D and Roberts A:
Targeting BCL2 for the treatment of lymphoid malignancies. Semin
Hematol. 51:219–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yu EM, Kittai A and Tabbara IA: Chronic
lymphocytic leukemia: Current concepts. Anticancer Res.
35:5149–5165. 2015.PubMed/NCBI
|
|
60
|
Hallek M: Chronic lymphocytic leukemia:
2015 Update on diagnosis, risk stratification, and treatment. Am J
Hematol. 90:446–460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
